fashion -WSS

fashion

author：focus 2025-09-28 15:06:37 - browse：5757

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into the fast-growing field of using targeted doses of radiation to treat cancer.

RayzeBio, which raised about $350 million in a September initial public offering, is working in radiopharmaceuticals, which pair the tumor-killing power of radiation with the precision of targeted cancer therapies. The company is currently running a pivotal trial of its most advanced drug, RYZ101, in neuroendocrine cancer and has a pipeline of treatments for kidney, liver, and other cancers.

Bristol Myers will pay $62.50 in cash per share of RayzeBio, a roughly 115% premium to the company’s recent trading and more than triple the company’s IPO price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Victims of gun violence feel impacts long after bullet wound

WSS

Food makers to regulators: Ultra

Ambulance rides for just $100? Advisers want major billing fixes

UCSF medical school apologizes for unethical prisoner experiments

New Covid vaccine is recommended for everyone 6 months or older

Pig kidney works a record two months in donated body

Extreme heat events are a public health emergency

entertainment

fashion

focus

Supreme Court strikes down use of affirmative action

White House touts steps to stem shortages of cancer treatments

Affirmative action in medical school literally saved lives

Food makers to regulators: Ultra

Dobbs anniversary: the lost opportunity of abortion as health care

A clever new way to fix Medicaid and graduate medical education

Moonlake's readout produced a cash windfall. Risks remain

Will the IRA bring competition to the biologics market?

What does generative AI mean for health care? We asked experts

Excited delirium, Elijah McClain, and emergency physicians

focus

Diverse clinical trials: Why aren’t we there yet?

Food makers to regulators: Ultra

PEPFAR is under serious threat — and so is global health

Long Covid needs a new name — and a new frame

Food makers to regulators: Ultra

Diversify hospital leadership teams to protect BIPOC patient health

focus

hotspot

hotspot

entertainment